Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TTY Biopharm CoROCO:4105 +0.39%83 Days Payable is 40.56 as of Mar. 2026, which is 13% above its 10-year median of 35.97. GuruFocus rates ROCO:4105 with a GF Score™ of 83/100 and a GF Value™ of NT$87.56 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 925 Drug Manufacturers companies, TTY Biopharm Co ranks worse than 88.32% on this metric.
The historical rank and industry rank for TTY Biopharm Co's Days Payable or its related term are showing as below:
ROCO:4105'
s Days Payable Range Over the Past 10 Years
Min: 23.3 Med: 35.97 Max: 40.83
Current: 31.71
During the past 13 years, TTY Biopharm Co's highest Days Payable was 40.83. The lowest was 23.30. And the median was 35.97.
ROCO:4105's Days Payable is ranked worse than 88.32% of 925
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs ROCO:4105: 31.71
TTY Biopharm Co's Days Payable
increased
from Mar. 2025 (32.45) to Mar. 2026 (40.56).
It may suggest that TTY Biopharm Codelayed paying its suppliers.
TTY Biopharm Co Days Payable Related Terms
TTY Biopharm Co Days Payable Historical Data
* Premium members only.
The historical data trend for TTY Biopharm Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, TTY Biopharm Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TTY Biopharm Co Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TTY Biopharm Co's Days Payable distribution charts can be found below:
* The bar in red indicates where TTY Biopharm Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
TTY Biopharm Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TTY Biopharm Co (ROCO:4105) has a Days Payable of 40.56 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on TTY Biopharm Co and its competitors. This is 13% above median its historical median of 35.97. Over the past decade, TTY Biopharm Co's Days Payable has ranged from 23.30 to 40.83. According to the industry distribution chart, TTY Biopharm Co ranks #817 out of 925 companies in the Drug Manufacturers industry, placing it in the top 88.3%.
Is TTY Biopharm Co's Days Payable too high?
TTY Biopharm Co's current Days Payable of 40.56 is 13% above median its 10-year median of 35.97. Over the past 10 years, this metric has ranged from a low of 23.30 to a high of 40.83. The Drug Manufacturers industry median Days Payable is 90.38. TTY Biopharm Co's value of 40.56 is 55.1% below this industry median. Based on the distribution chart, TTY Biopharm Co ranks #817 out of 925 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, TTY Biopharm Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TTY Biopharm Co's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, TTY Biopharm Co ranks #817 out of 925 companies for Days Payable. This places TTY Biopharm Co in the lower half of its industry. The industry median Days Payable is 90.38. TTY Biopharm Co's value of 40.56 is 55.1% below this benchmark. Historically, TTY Biopharm Co's own Days Payable has ranged from 23.30 to 40.83 over the past decade. While the company's 10-year median is 35.97 vs. the industry median of 90.38, TTY Biopharm Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TTY Biopharm Co's current Days Payable of 40.56 is 55.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on TTY Biopharm Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TTY Biopharm Co's current Days Payable is 40.56, which is 13% above median its own 10-year median of 35.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TTY Biopharm Co stock overvalued right now?
Based on GuruFocus' analysis, TTY Biopharm Co (ROCO:4105) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.56, compared to a current price of NT$78.10 — trading 10.8% below its estimated fair value. The current Days Payable is 40.56, which is 13% above median its 10-year median of 35.97 and 55.1% below the Drug Manufacturers industry median of 90.38. TTY Biopharm Co's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For TTY Biopharm Co (ROCO:4105), the current Days Payable is 40.56 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TTY Biopharm Co (ROCO:4105) Overvalued in 2026?
Based on GuruFocus' analysis, TTY Biopharm Co stock appears to be undervalued.
The current stock price of NT$78.10 is trading 10.8% below its estimated GF Value™ of NT$87.56.
GuruFocus considers TTY Biopharm Co to be Modestly Undervalued.
Key valuation signals for ROCO:4105:
Days Payable: 40.56 (13% above median its 10-year median of 35.97)
GF Value™: NT$87.56 vs. price of NT$78.10 (10.8% below fair value)
Industry Position: 55.1% below the Drug Manufacturers median (#817 of 925)
No single metric tells the full story. See the ROCO:4105 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segments includes Oncology Business unit, Health Care Business unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business unit segment. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in America. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.
83GF Score
Get the complete analysis for ROCO:4105
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4105 has been successfully added to your 
